BioteBTMD -1.32%72 3-Year RORE % is 36.11 as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 72/100 and a GF Value™ of $3.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Biote ranks better than 80.5% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Biote's 3-Year RORE % for the quarter that ended in Mar. 2026 was 36.11%.
The industry rank for Biote's 3-Year RORE % or its related term are showing as below:
BTMD's 3-Year RORE % is ranked better than 80.5% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: -0.32
vs BTMD: 36.11
Biote (NAS:BTMD) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Biote 3-Year RORE % Related Terms
Biote 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Biote's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMD vs DCGO, PIII, EHSI: 3-Year RORE % Comparison
For the Medical Care Facilities subindustry, Biote's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Biote's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Biote (BTMD) has a 3-Year RORE % of 36.11 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #118 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 19.5%.
Is Biote's 3-Year RORE % too high?
Biote's current 3-Year RORE % is 36.11. Based on the distribution chart, Biote ranks #118 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Biote has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's 3-Year RORE % compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #118 out of 605 companies for 3-Year RORE %. This places Biote in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
A good 3-Year RORE % depends on the Healthcare Providers & Services industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biote and its competitors. Biote's current 3-Year RORE % is 36.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.25 — trading 26.7% below its estimated fair value. The current 3-Year RORE % is 36.11. Biote's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Biote (BTMD), the current 3-Year RORE % is 36.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $2.25 is trading 26.7% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Modestly Undervalued.
Key valuation signals for BTMD:
3-Year RORE %: 36.11
GF Value™: $3.07 vs. price of $2.25 (26.7% below fair value)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
72GF Score
Get the complete analysis for BTMD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
